Hygieia Group Limited (1650) AI Stock Analysis

• Market Cap: HK$242.00M
• Dividend Yield: 10.17%
• Average Volume (3M): 484.80K
• Price to Earnings (P/E): 3.2
• Beta (1Y): 0.06
• Revenue Growth: 7.94%
• EPS Growth: 18.60%
• Country: HK
• Employees: 2,690
• Sector: Industrials
• Sector Strength: 72
• Industry: Consulting Services
• EPS (TTM): <0.01
• Shares Outstanding: 2,000,000,000
• 10 Day Avg. Volume: 704,800
• 30 Day Avg. Volume: 484,800
• PEG Ratio: 0.34
• Price to Book (P/B): 0.92
• Price to Sales (P/S): 0.34
• P/FCF Ratio: 17.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: HK$0.13 ▲(5.83% Upside)
• Action: Upgraded Date: 12/19/25
• Date: Action: Upgraded 12/19/25

The overall stock score of 71 reflects strong technical indicators and a solid financial foundation, despite challenges in profitability margins. The high dividend yield enhances the stock's attractiveness, while the moderate P/E ratio suggests reasonable valuation. The absence of earnings call and corporate events data did not impact the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion and stability.

Strong Equity Position

A strong equity position with low leverage enhances financial stability, providing flexibility for future investments and growth opportunities.

Cash Flow Generation

Strong cash generation relative to net income ensures liquidity and supports ongoing operations, investments, and potential debt reduction.

Negative Factors

Profitability Margins

Low profitability margins suggest challenges in converting revenue into profit, potentially limiting reinvestment and shareholder returns.

Operational Inefficiencies

Low EBIT and EBITDA margins indicate potential inefficiencies in operations, which could hinder profitability and require strategic improvements.

Free Cash Flow Limitations

Limited free cash flow relative to net income may restrict the company's ability to invest in growth opportunities and manage financial obligations.

Hygieia Group Limited Business Overview & Revenue Model

Company Description

Hygieia Group Limited (1650) is a company focused on delivering innovative healthcare solutions, primarily in the field of medical technologies and health services. Operating within the healthcare sector, the company specializes in developing advanced diagnostic tools, patient monitoring systems, and telehealth services aimed at improving patient outcomes and optimizing healthcare delivery. With a commitment to enhancing the quality of care, Hygieia Group Limited is positioned as a key player in the evolving landscape of health technology.

How the Company Makes Money

Hygieia Group Limited generates revenue through multiple streams, primarily by selling its proprietary medical devices and diagnostic tools to healthcare providers, hospitals, and clinics. The company also offers subscription-based telehealth services, which provide ongoing revenue through monthly fees for access to its digital health platforms. Additionally, Hygieia Group Limited has entered into strategic partnerships with pharmaceutical companies and research institutions, allowing for collaborative development projects that can lead to licensing agreements and shared revenue models. These partnerships enhance the company’s research capabilities and expand its market reach, thereby contributing significantly to its earnings.

Hygieia Group Limited Financial Statement Overview

Summary

Hygieia Group Limited demonstrates a solid financial foundation with strong equity and low leverage, providing stability. Revenue growth is evident, but profitability margins are under pressure, indicating a need for operational improvements. Cash flow generation is healthy, though there is potential to enhance free cash flow.

Income Statement

The company has shown a consistent increase in revenue over the past years, with a notable revenue growth rate of 12.27% from 2023 to 2024. Gross profit margin improved slightly to 12.91% in 2024, indicating better cost management. However, the net profit margin remains low at 1.01%, suggesting challenges in converting revenue into profit. The EBIT and EBITDA margins are also relatively low, reflecting potential inefficiencies in operations.

Balance Sheet

The balance sheet reflects a strong equity position with an equity ratio of 67.87% in 2024, indicating financial stability. The debt-to-equity ratio is low at 0.14, suggesting conservative leverage. Return on equity improved to 2.72%, but remains modest, highlighting room for enhancing shareholder returns.

Cash Flow

Operating cash flow has improved, with a positive free cash flow growth rate of 2.74% from 2023 to 2024. The operating cash flow to net income ratio is 2.87, indicating strong cash generation relative to net income. However, the free cash flow to net income ratio is 1.98, suggesting that while cash flow is positive, there is limited free cash flow relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	77.07M	74.70M	66.54M	63.42M	71.61M	72.61M
Gross Profit	11.80M	9.65M	8.99M	8.60M	14.45M	22.16M
EBITDA	2.37M	516.00K	3.24M	1.48M	9.02M	12.38M
Net Income	1.75M	756.00K	454.00K	-1.60M	5.14M	8.80M
Balance Sheet
Total Assets	37.74M	40.99M	44.48M	46.87M	56.53M	50.16M
Cash, Cash Equivalents and Short-Term Investments	15.13M	18.43M	22.58M	27.52M	31.02M	22.63M
Total Debt	2.85M	3.90M	6.04M	7.52M	9.47M	7.45M
Total Liabilities	11.69M	13.06M	14.38M	15.27M	18.84M	17.57M
Stockholders Equity	25.90M	27.82M	30.05M	31.60M	37.70M	32.55M
Cash Flow
Free Cash Flow	7.26M	1.50M	146.00K	4.14M	8.79M	6.58M
Operating Cash Flow	7.68M	2.17M	1.04M	5.08M	9.87M	7.22M
Investing Cash Flow	2.82M	2.60M	-815.00K	-10.41M	1.72M	-3.11M
Financing Cash Flow	-8.10M	-6.64M	-5.52M	-8.19M	-675.00K	3.43M

Hygieia Group Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.12
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1650, the sentiment is Neutral. The current price of 0.12 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.12, and above the 200-day MA of 0.10, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 41.93 is Neutral, neither overbought nor oversold. The STOCH value of 35.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1650.

Hygieia Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1650	71 Outperform	HK$242.00M	3.23	6.50%	10.17%	7.94%	18.60%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
8501	50 Neutral	HK$120.75M	-3.32	-7.39%	―	50.50%	27.48%
1376	47 Neutral	HK$155.00M	2.26	-10.63%	―	1.93%	-158.33%
8455	47 Neutral	HK$106.56M	-4.63	-601.82%	―	4.00%	13.57%
3893	46 Neutral	HK$321.27M	-0.40	―	―	-24.93%	-72.69%
1867	42 Neutral	HK$337.64M	-3.32	-78.46%	―	-30.47%	-57.80%